Table 1. .
Demographics | NVSN (N = 13 916a) | SUPERNOVA (N = 635a) | ||||
---|---|---|---|---|---|---|
With AGE Code (n = 7572), n (%) | Without AGE Code (n = 6344), n (%) | aORb (95% CI) | With AGE Code (n = 368), n (%) | Without AGE Code (n = 267), n (%) | aORc (95% CI) | |
Male | 4166 (55.0) | 3325 (52.4) | … | 340 (92.4) | 243 (91.0) | … |
Female | 3406 (45.0) | 3019 (47.6) | … | 28 (7.6) | 24 (9.0) | … |
Median aged (25th IQR, 75th IQR) | 18 (9, 31) | 18 (9, 33) | 1.01 (1.01, 1.02) | 63 (53, 70) | 64 (55, 71) | … |
Ethnicity | n = 7563 | n = 6337 | n = 367 | n = 267 | ||
Non-Hispanic | 4468 (59.1) | 4299 (67.8) | … | 324 (88.3) | 221 (82.8) | … |
Hispanic | 3095 (40.9) | 2038 (32.2) | … | 43 (11.7) | 46 (17.2) | … |
Race | n = 6374 | n = 5935 | n = 358 | n = 257 | ||
White | 3148 (46.8) | 2606 (43.9) | … | 182 (50.8) | 119 (46.3) | … |
Black | 2474 (36.7) | 2381 (40.1) | … | 163 (45.5) | 126 (49.0) | … |
Asian/NH/PI | 183 (2.7) | 121 (2.0) | … | 2 (0.6) | 1 (0.4) | … |
AI/AN | 14 (0.2) | 11 (0.2) | … | 1 (0.3) | 1 (0.4) | … |
Other | 915 (13.6) | 816 (13.8) | … | 10 (2.8) | 10 (3.9) | … |
Setting | ||||||
Inpatient | 1692 (22.4) | 1162 (18.3 | Ref | 322 (87.5) | 252 (94.4) | Ref |
ED | 5880 (77.7) | 5182 (81.7) | 0.81 (0.73, 0.90) | 46 (12.5) | 15 (5.6) | 2.24 (1.16, 4.32) |
AGE symptoms documented | n = 7564 | n = 6324 | ||||
Diarrhea with or without vomiting | … | … | Ref | 357 (97.0) | 228 (86.0) | Ref |
Vomiting alone | 763 (10.1) | 3408 (53.9) | 0.08 (0.07, 0.09) | 11 (3.0) | 37 (14.0) | 0.21 (0.10, 0.42) |
Immunocompromising condition presente | NA | NA | … | 85 (23.1) | 53(19.9) | … |
Severe AGEf | n = 6621 | n = 5658 | NA | NA | ||
Yes | 3508 (53.0) | 1796 (31.8) | … | NA | NA | … |
Siteg | ||||||
1 | 1020 (13.5) | 1389 (21.9) | Ref | 72 (19.6) | 32 (12.0) | Ref |
2 | 360 (4.8) | 754 (11.9) | 0.58 (0.48, 0.69) | 26 (7.1) | 38 (14.2) | 0.30 (0.15, 0.61) |
3 | 1190 (15.7) | 1309 (20.6) | 1.31 (1.14, 1.51) | 221 (60.1) | 129 (48.3) | 0.68 (0.41, 1.12) |
4 | 331 (4.4) | 220 (3.5) | 2.37 (1.85, 3.00) | 49 (13.3) | 68 (25.5) | 0.35 (0.20, 0.63) |
5 | 1855 (24.5) | 943 (14.9) | 2.75 (2.40, 3.15) | … | … | … |
6 | 1564 (20.7) | 1247 (19.7) | 1.88 (1.63, 2.17) | … | … | … |
7 | 1252 (16.5) | 482 (7.6) | 4.08 (3.36, 5.00) | … | … | … |
Surveillance yearh | ||||||
2011 | 1225 (16.2) | 1105 (17.4) | Ref | NA | NA | … |
2012 | 1803 (23.8) | 1437 (22.7) | 1.05 (0.91, 1.20) | NA | NA | … |
2013 | 1822 (24.1) | 1496 (23.6) | 1.27 (1.10, 1.45) | NA | NA | … |
2014 | 1916 (25.3) | 1471 (23.2) | 1.26 (1.09, 1.44) | NA | NA | … |
2015 (incomplete) | 806 (10.6) | 835 (13.2) | 1.11 (0.94, 1.30) | NA | NA | … |
2016 | NA | NA | … | 306 (83.2) | 259 (63.3) | … |
2017 (incomplete) | NA | NA | … | 62 (16.9) | 150 (36.7) | … |
All crude ORs and year-specific aORs are provided in Supplementary Table 4.Abbrevations: AGE, acute gastroenteritis; AI/AN, American Indian/Alaska Native; aOR, adjusted odds ratio; CI, confidence interval; ED, emergency department; IQR, interquartile range; NA, not applicable; NH/PI, Native Hawaiian/Pacific Islander; NVSN, New Vaccine Surveillance Network; Ref, reference; SUPERNOVA, Surveillance Platform for Enteric and Respiratory Infections in the Veterans Affairs Population.
aUnless otherwise specified.
bNVSN model adjusted for age, sex, race, ethnicity, year, site, healthcare setting (inpatient vs ED visit), presence of vomiting without diarrhea, and severe AGE.
cSUPERNOVA model adjusted for age, sex, race, ethnicity, site, healthcare setting, and presence of vomiting without diarrhea.
dAge in months for NVSN and age in years for SUPERNOVA.
eImmunocompromising condition present defined as organ transplant, cancer, HIV, and immunosuppressive therapy
fSevere AGE defined as modified Vesikari score ≥11 [15].
gFour SUPERNOVA sites were included in the study: Atlanta VA Medical Center, James J. Peters VA Medical Center, VA Greater Los Angeles Health System (Los Angeles, California), and the Michael E. DeBakey VA Medical Center (Houston, Texas).
hSurveillance year is 1 December–30 November for NVSN and 1 December–30 September for SUPERNOVA.